Plasmid for the Production of Proteins of SARS-CoV-2 Proteome

University of Notre Dame Background
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of the coronavirus disease of 2019 (COVID-19). The WHO declared COVID-19 a pandemic in March, 2020. By July 2021 there had been >190 million confirmed cases and 4.1 million fatalities due to the disease. Despite multiple COVID-19 vaccines being available, COVID-19 therapeutic options to treat the disease directly are lacking.
Initial COVID-19 therapeutics discovery efforts repurposed existing antiviral treatments. Only one treatment with modest efficacy has been FDA approved, emphasizing the need for drugs that are designed expressly for SARS-CoV-2. Access to the different proteins of SARS-CoV-2 in high purity and sufficient amounts is required to identify promising candidates for such drugs.
Technology Overview
The University of Notre Dame researchers optimized methods for the production and purification of nine discrete proteins of the SARS-CoV-2 proteome essential for virion assembly during its replication. The discrete proteins’ genes were cloned and expressed in Escherichia coli for production and subsequent purification. These proteins are intended for experimental validation of small-molecule binders as molecular-template hits. Availability of these proteins in soluble forms provides the opportunity for discoveries of novel templates, potentially resulting in anti-COVID-19 pharmaceuticals.

Further Details:
Production of Proteins of the SARS-CoV-2 Proteome for Drug Discovery
Benefits

Tag-free, soluble proteins isolation
Method is capable of discrete proteins from PP1a and PP1ab

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More